P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Seung-Yul Lee; Young-Hoon Jeong; Kyeong  Ho Yun; Jae  Young Cho; Diana Gorog; Dominick J. Angiolillo; Kim Jin Won; Yangsoo  Jang

doi:10.1016/j.jcin.2023.05.035

P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Seung-Yul Lee, Young-Hoon Jeong, Kyeong Ho Yun, Jae Young Cho, Diana Gorog, Dominick J. Angiolillo, Kim Jin Won, Yangsoo Jang

Research output: Contribution to journal › Article › peer-review

3 Downloads (Pure)

Abstract

This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.

Original language	English
Pages (from-to)	1845-1855
Number of pages	11
Journal	JACC: Cardiovascular Interventions
Volume	16
Issue number	15
Early online date	14 Aug 2023
DOIs	https://doi.org/10.1016/j.jcin.2023.05.035
Publication status	Published - 14 Aug 2023

Access to Document

10.1016/j.jcin.2023.05.035Licence: Unspecified

Accepted_Manuscript
© 2023 by the American College of Cardiology Foundation. Published by Elsevier. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1016/j.jcin.2023.05.035
Accepted author manuscript, 1.74 MBLicence: Unspecified

Cite this

@article{05d55f616fb94db79ed87c5efe4e865f,

title = "P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study",

abstract = "This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.",

author = "Seung-Yul Lee and Young-Hoon Jeong and {Ho Yun}, Kyeong and {Young Cho}, Jae and Diana Gorog and Angiolillo, {Dominick J.} and {Jin Won}, Kim and Yangsoo Jang",

note = "{\textcopyright} 2023 by the American College of Cardiology Foundation. Published by Elsevier. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1016/j.jcin.2023.05.035",

year = "2023",

month = aug,

day = "14",

doi = "10.1016/j.jcin.2023.05.035",

language = "English",

volume = "16",

pages = "1845--1855",

journal = "JACC: Cardiovascular Interventions",

issn = "1876-7605",

publisher = "Elsevier",

number = "15",

}

TY - JOUR

T1 - P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

AU - Lee, Seung-Yul

AU - Jeong, Young-Hoon

AU - Ho Yun, Kyeong

AU - Young Cho, Jae

AU - Gorog, Diana

AU - Angiolillo, Dominick J.

AU - Jin Won, Kim

AU - Jang, Yangsoo

N1 - © 2023 by the American College of Cardiology Foundation. Published by Elsevier. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1016/j.jcin.2023.05.035

PY - 2023/8/14

Y1 - 2023/8/14

N2 - This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.

AB - This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.

U2 - 10.1016/j.jcin.2023.05.035

DO - 10.1016/j.jcin.2023.05.035

M3 - Article

SN - 1876-7605

VL - 16

SP - 1845

EP - 1855

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 15

ER -

P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Abstract

Access to Document

Fingerprint

Cite this